The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Different prevalence of BRAF and NRAS somatic mutations in melanomas according to the patients’ origin.
Giuseppe Palmieri
No relevant relationships to disclose
Amelia Lissia
No relevant relationships to disclose
Antonio Cossu
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Gerardo Botti
No relevant relationships to disclose
Corrado Caraco
No relevant relationships to disclose
Nicola Mozzillo
No relevant relationships to disclose
Fabrizio Ayala
No relevant relationships to disclose
Annamaria Anniciello
No relevant relationships to disclose
Vincenzo De Giorgi
No relevant relationships to disclose
Daniela Massi
No relevant relationships to disclose
Ignazio Stanganelli
No relevant relationships to disclose
Corrado Rubino
No relevant relationships to disclose
Grazia Palomba
No relevant relationships to disclose
MariaCristina Sini
No relevant relationships to disclose
Antonella Manca
No relevant relationships to disclose
Maria Colombino
No relevant relationships to disclose